Human Antibodies from GENOVAC and Ligand Pharmaceutical
Partnering for best-in-class discovery and development services
Combining GENOVAC Antibody Technology with Ligand’s OmniAb™ transgenic rodents provides clients with accelerated discovery, in vivo optimization for therapeutic efficacy and manufacturability, and fully human sequences for safety and reduced immunogenicity.
A variety of immunization protocols have been applied successfully with OmniAb animals, including DNA, peptide, protein, or cell immunization.The technology also has been used to complete multiple projects with OmniRat™, OmniFlic™ and OmniMouse™ antibody platforms.
By establishing a collaborative workflow between the end user, Ligand and the breeding facility, GENOVAC can take a project from a target sequence to immunization, fusion, screening and delivery of the desired antibody.
Objective: Generate a diverse panel of mAbs specific for different members of the human CEACAM family in the OmniRat Antibody Platform.
Target: Human CEACAM5
Method: Genetic Immunization of OmniRats
Result: Similar epitope coverage of cross-reactive mAbs with OmniRats and Wistar
T-Cell Receptor (TCR) complex
Objective: Generating monoclonal antibodies using the OmniRat Antibody Platform against the human TCR-complex with cross reactivity to the Cynomolgus TCR-complex.
Method: Genetic immunization of OmniRats by co-immunization with CD3 chains
The TCR–complex is composed of 6 different polypeptides on the surface of T-cells:
- alpha & beta fragments
- CD3 gamma, delta, epsilon
- Zeta chains
OmniAb Strains vs. Target Classes
OmniRats Kappa & Lambda: Ligand-Receptor Protein Complex
Good anti-protein complex-specific response, antigen-dependent strain response, multi-plexed for complex-only selection.
OmniRats Kappa & Lambda: GPCR
Good anti-GPCR response, antigen-dependent strain response, multi-plexed, cross-reactive, real-time screening, titer not linear predictor of specific antibody yield.
OmniRat Kappa & Lambda, Kappa/Lambda, OmniFlic: Type I TM Protein
Good anti-type I TM response, antigen-dependent strain response, titer not linear predictor of specific antibody yield.
GENOVAC delivers hybridoma and/or B cells for every antibody project. It also provides the following complementary services:
- Antibody sequencing
- Recombinant antibody production
- Antibody purification from hybridomas
- Deep sequencing of lymphocytes of immunized animals for the OmniFlic™ antibody platform in collaboration with TeneoBio
Complete our online form for a complimentary antibody target analysis.